20221 10108htmlOn the 1st, the China National Medical Products Administration approved Hualing Pharmaceutical's 11 new drug Dogliasetin tablets to be launched, which is suitable for improving blood sugar control in adult 2htmltype 1 diabetes patients. 2022 10 2 2 bottom , Huatang Ning ® (dogliadetin tablets) began to be launched on sale, starting to benefit patients.
diabetes is a group of diseases that are guided by the joint action of multiple factors insulin deficiency or hindering the function of insulin. The types of diabetes are roughly divided into 1htmltype 1 diabetes, 2htmltype 1 diabetes, gestational diabetes and other special diabetes. According to data, China has about 1.1400 million diabetic patients, accounting for about 1% of 27html of diabetic patients worldwide, and has become a country with the most diabetes patients in the world. Among them, 2 html type 1 diabetes is the main one, and the incidence is mostly after 35 after 1 year old, accounting for more than 1% of the total number of patients 90 [1].
Diabetes harms human health, and the long-term course of the disease can easily lead to damage to multiple target organs such as the retina, kidney, Neural System, , cardiovascular and cerebrovascular system, and is the main cause of cardiovascular and cerebrovascular events, end-stage renal disease, amputation, and blindness in my country. At the same time, acute metabolic disorders may occur when the condition is severe or stressed, such as diabetic ketoacidosis , hyperglycemia and hyperosmotic state, etc., which may be life-threatening.
Dogliasetin is an activator of glucose kinase (GK). Glucokinase is an important target for regulating the secretion of sugar hormones in the human body. It can sense changes in blood sugar concentration in the body and activate the blood sugar regulation system to maintain blood sugar homeostasis, which is mainly expressed in the human pancreas and liver. Although there are many types of diabetes drugs, there are different applications and differences in various drugs. The research and development of hypoglycemia drugs still needs to be continued. Glucokinase activators have changed the concept of diabetes treatment, and in recent years it has become a hot topic in the research and development of new diabetes drugs.
dogliadetin acts on glucose kinase targets in the storage and output organs of glucose storage and output organs such as pancreatic islets, intestinal endocrine cells, and liver, improves the secretion of impaired glucose-stimulated insulin and GLP-1GLP-1, thereby improving β-cell function and reducing insulin resistance, thereby improving blood sugar homeostasis in patients with 2, and has a mechanism of action to reshape the physiological regulation of blood sugar balance. The drug's launch has provided new treatment options for patients with 2htmltype 1 diabetes.
Reference materials:
[1] Diabetes Branch of Chinese Medical Association , National Grassroots Diabetes Prevention and Control Management Office . National Grassroots Diabetes Prevention and Control Management Manual (2022) [J]. Chinese Journal of Internal Medicine , 2022, 61 (7) : 717-748.
[2] Dogliasetin Instructions
